Core Viewpoint - Weigao Orthopedics announced that the signing ceremony for its surgical robot, developed by Beijing Weigao Smart Technology Co., Ltd., at the 2025 COA conference did not result in actual sales, and the company is not included in the consolidated financial statements of the listed company [1] Group 1: Product Development and Technology - The orthopedic robot utilizes AI three-dimensional modeling, automatically picks feature points, and employs optimized matching algorithms, providing strong end-effector power that aligns closely with clinical surgical needs [1] - The company is enhancing market integration with its group orthopedic surgical robot company to promote product education and hospital deployment [1] - The five-in-one ultrasonic bone power system, a core technology product acquired from Jiesibai'er Company, is expected to receive certification in the second half of 2025, integrating five major functions: ultrasonic bone knife, power, milling, perfusion pump, and negative pressure absorption [1] Group 2: Financial and Corporate Structure - As of the end of 2025, the sales revenue from the five-in-one ultrasonic bone power system will not be reflected in the listed company's annual report due to the incomplete equity change of Jiesibai'er [1]

Core Viewpoint - Weigao Orthopedics is actively engaged in clinical research and technical collaboration in the field of surgical robots for spinal and joint surgeries, having authorized key technical data of its core products to multiple surgical robot companies [1] Group 1 - Weigao Orthopedics has been asked by investors about its collaboration with surgical robot companies [1] - The company has established clinical research and technical cooperation in the field of surgical robots [1] - Key technical data of core products has been authorized to several surgical robot companies [1]

Group 1 - The core point of the article is that Weigao Orthopedics is currently not generating sales from its surgical robot products, which are managed by the group company, and that new products like the ultrasonic bone knife will not reflect in the 2024 annual report but are expected to be sold by 2026 [1] Group 2 - Weigao Orthopedics has engaged in various collaborations with surgical robot companies, indicating a strategic approach to entering the surgical robotics market [1] - The company has recently acquired a minimally invasive orthopedic production line, which includes the ultrasonic bone knife from Jiesibai'er [1] - The strategic signing ceremony for the surgical robot deployment in hospitals took place at the 2025 COA conference, highlighting the company's future plans in this sector [1]

Group 1 - The company plans to invest 60 million yuan, accounting for 20% of the total capital contribution, in a partnership with several private equity firms to establish Jiaxing Xinwei Chuangying Equity Investment Partnership (Limited Partnership) [1] - The partnership has completed the necessary business registration and obtained a business license from the local market supervision authority, with a total capital of 300 million yuan [2] - The partnership is yet to have specific investment projects and the company has not yet made its capital contribution [2][4] Group 2 - The company will closely monitor the fund's operations, management, investment decisions, and post-investment management to mitigate investment risks [3] - There is uncertainty regarding the investment progress and project completion due to various factors such as macroeconomic conditions and industry cycles [3] - As of now, there are no specific external investment projects associated with the partnership [4]

证券代码：688161 证券简称：威高骨科 公告编号：2026-001 山东威高骨科材料股份有限公司 与私募基金合作投资事项进展公告 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司近日收到信金顺致私募基金管理（北京）有限公司的通知，嘉兴信威创 盈股权投资合伙企业(有限合伙)已完成相关工商登记手续并取得平湖市市场监 督管理局颁发的《营业执照》。具体信息如下： 企业名称：嘉兴信威创盈股权投资合伙企业(有限合伙) 执行事务合伙人：信金顺致私募基金管理(北京)有限公司(委派代表:高卓 群) 统一社会信用代码：91330482MAK5QL1F69 出资额：叁亿元整 企业类型：有限合伙企业 投资标的名称 嘉兴信威创盈股权投资合伙企业(有限合伙) 投资金额（万元） 6,000.00 投资进展阶段 完成 终止 交易要素变更 √进展 特别风险提示（如有请勾选） 募集失败 未能完成备案登记 提前终止 发生重大变更 其他： 一、合作投资基本概述情况 山东威高骨科材料股份有限公司（以下简称"公司"）拟与信金顺致私募基 金管理（北 ...

Group 1 - The core viewpoint of the news is that Weigao Orthopedics has seen a stock price increase of 5.01%, reaching 29.32 CNY per share, with a total market capitalization of 11.728 billion CNY [1] - Weigao Orthopedics specializes in the research, production, and sales of orthopedic medical devices, with its main revenue sources being joints (29.01%), spine (28.99%), sports medicine and tissue repair (19.11%), trauma (16.64%), and others (6.10%) [1] - The company was established on April 6, 2005, and went public on June 30, 2021 [1] Group 2 - Among the top ten circulating shareholders of Weigao Orthopedics, Penghua Fund has a fund that entered the list, holding 1.0961 million shares, which is 0.27% of the circulating shares [2] - The Penghua Medical Technology Stock A fund has achieved a year-to-date return of 68.28%, ranking 197 out of 4189 in its category [2] - The fund was established on June 2, 2015, and has a current scale of 1.921 billion CNY [2] Group 3 - The fund manager of Penghua Medical Technology Stock A is Jin Xiaofei, who has a tenure of 9 years and 198 days, with the fund's total asset size at 5.375 billion CNY [3] - During Jin Xiaofei's tenure, the best fund return was 234.14%, while the worst return was -0.92% [3]

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

Market Performance - The US stock market continued its post-Christmas pullback, with all three major indices closing lower, marking a subdued end to 2025. The S&P 500 index fell by 0.74% to 6845.5 points, the Nasdaq Composite dropped by 0.76% to 23241.99 points, and the Dow Jones Industrial Average decreased by 0.63% to 48063.29 points [1]. - For the year, the S&P 500 recorded an annual increase of 16.39%, while the Nasdaq managed a 20.36% rise, achieving over 20% growth for three consecutive years. The Dow Jones also rose by 12.97%, marking a similar performance for the third year in a row [3]. Individual Stock Performance - Among the top performers in the S&P 500, four storage giants—SanDisk, Western Digital, Micron Technology, and Seagate Technology—led the annual gains. Semiconductor stocks like Lam Research, AI application leader Palantir, and Comfort Systems, which provides HVAC solutions for data centers, also featured prominently [3]. - In the tech sector, only Google and Nvidia among the "Big Seven" tech companies outperformed the benchmark index in 2025 [8]. Commodity and Sector Movements - US silver futures experienced a significant drop of 9% due to a second margin increase by the CME Group within a week, negatively impacting the mining sector. Companies like Endeavour Silver and Silvercorp Metals saw declines of over 4% and 2.8%, respectively [11]. Chinese Stocks - The Nasdaq Golden Dragon China Index closed down 1.13% but recorded an annual increase of 11.33%. Notable Chinese stocks included Alibaba, which rose over 75%, and Netease, which increased by 58.28% [12]. Corporate News - Warren Buffett officially retired as CEO of Berkshire Hathaway on December 31, 2025, after a long tenure, although he will remain as chairman of the board [13]. - Tesla achieved a milestone with a driver completing a coast-to-coast journey using full self-driving technology, marking a significant advancement in autonomous vehicle capabilities [15]. - Nvidia and AMD are expected to enter a "year-long price increase cycle" for GPUs, driven by rising memory costs, with flagship models potentially reaching prices as high as $5000 [16]. - Trump Media & Technology Group announced plans to issue a new cryptocurrency to shareholders, despite a significant annual decline in stock value [17]. - Brookfield Asset Management is launching a cloud computing business to challenge tech giants like Amazon, aiming to reduce AI development costs [18]. - Uber is in talks to acquire the parking app SpotHero, which could create synergies between ride-hailing and parking services [19].

Group 1 - The company held its third extraordinary general meeting of shareholders on December 29, 2025, in Shanghai, with no resolutions being rejected [2] - The meeting was convened by the board of directors and conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - The meeting was attended by 7 out of 8 current directors, with the board secretary and other executives present, while one independent director was absent due to work commitments [3] Group 2 - A key resolution passed during the meeting was regarding the change of certain fundraising projects and the acquisition of equity in Suzhou Jiesibai Medical Technology Co., Ltd., which was approved [4] - The voting for the resolutions was conducted as ordinary resolutions, requiring more than half of the voting shares represented at the meeting to pass [5] Group 3 - The company signed a tripartite supervision agreement for the storage of raised funds, ensuring effective management and protection of investor rights [7][11] - The company was approved to publicly issue 41.4142 million shares at a price of RMB 36.22 per share, raising a total of RMB 1.5 billion, with a net amount of RMB 1.382 billion after deducting issuance costs [8][9] - A special account for the raised funds was established, which is exclusively for the storage and use of funds related to the acquisition and capital increase project [10][12] Group 4 - The tripartite agreement involves the company, China Agricultural Bank, and Huatai United Securities, outlining the management and supervision of the raised funds [12] - The agreement stipulates that any withdrawal exceeding RMB 50 million or 20% of the net raised funds must be reported to the supervising party [14] - The agreement will remain effective until all funds are fully utilized and the account is legally closed [15]

Core Viewpoint - Weigao Orthopedics announced the convening of its third extraordinary shareholders' meeting on December 29, 2025, in Shanghai to review key proposals [1] Group 1 - The company will discuss the proposal to change part of the fundraising projects and to acquire equity in Suzhou Jiesbai Medical Technology Co., Ltd., along with plans for capital increase [1] - The election of Mr. Li Jinqiu as a non-independent director of the third board of directors will also be on the agenda [1]